Abed A.

Seven Bridges is the industry-leading unified bioinformatics solutions company accelerating precision medicine by enabling the understanding of biomedical data. Our platform, analytic tools, and services expertise are driving discovery and drug development at the world’s leading academic, biotechnology, government, hospitals, and pharmaceutical entities. Through our collaboration with the largest genomics projects, we connect the world’s biomedical information to enable the most efficient analysis at scale.

Next generation CRISPR technology for programmed cell death. Focused on developing therapies for infectious disease and the microbiome. Locus Biosciences’ novel approach to precision antimicrobials works by taking advantage of a part of an immune system present in many bacteria called the CRISPR-Cas system. The CRISPR-Cas system protects bacteria from invaders such as viruses by creating small strands of RNA called CRISPR RNAs, which match DNA sequences specific to a given invader. When the CRISPR RNAs find a match, they activate Cas proteins that cut the DNA. Locus Biosciences has developed a platform to design and deliver custom CRISPR-Cas systems directly to specific bacteria. Guided by the custom Locus Bio CRISPRs, the Type-I Cas proteins work to destroy bacterial DNA and cause the bacterial targets to “self-destruct”. Locus’ platform enables the development of antimicrobials which avoid currently known resistance mechanisms while leaving non-target bacteria unharmed. Built on prokaryotic technology for prokaryotic targets, Locus is advancing its platform to create therapeutics for critical-need therapeutic areas ranging from resistant bacterial infections to the microbiome.

Seven Bridges is the industry-leading unified bioinformatics solutions company accelerating precision medicine by enabling the understanding of biomedical data. Our platform, analytic tools, and services expertise are driving discovery and drug development at the world’s leading academic, biotechnology, government, hospitals, and pharmaceutical entities. Through our collaboration with the largest genomics projects, we connect the world’s biomedical information to enable the most efficient analysis at scale.

Next generation CRISPR technology for programmed cell death. Focused on developing therapies for infectious disease and the microbiome. Locus Biosciences’ novel approach to precision antimicrobials works by taking advantage of a part of an immune system present in many bacteria called the CRISPR-Cas system. The CRISPR-Cas system protects bacteria from invaders such as viruses by creating small strands of RNA called CRISPR RNAs, which match DNA sequences specific to a given invader. When the CRISPR RNAs find a match, they activate Cas proteins that cut the DNA. Locus Biosciences has developed a platform to design and deliver custom CRISPR-Cas systems directly to specific bacteria. Guided by the custom Locus Bio CRISPRs, the Type-I Cas proteins work to destroy bacterial DNA and cause the bacterial targets to “self-destruct”. Locus’ platform enables the development of antimicrobials which avoid currently known resistance mechanisms while leaving non-target bacteria unharmed. Built on prokaryotic technology for prokaryotic targets, Locus is advancing its platform to create therapeutics for critical-need therapeutic areas ranging from resistant bacterial infections to the microbiome.